Literature DB >> 33585095

Inflammatory Markers in Severity of Intracerebral Hemorrhage II: A Follow Up Study.

Jacob E Bernstein1, Jonathan D Browne2, Paras Savla1, James Wiginton1, Tye Patchana1, Dan E Miulli3, Margaret Rose Wacker3, Jason Duong3.   

Abstract

Introduction Spontaneous intracerebral hemorrhage (ICH) results in significant morbidity and mortality. The pathogenesis of brain injury after ICH is thought to be due to mechanical damage followed by ischemic, cytotoxic, and inflammatory changes in the underlying and surrounding tissue. Various inflammatory and non-inflammatory biomarkers have been studied as predictors and potential therapeutic targets for intracerebral hemorrhage. Our prior study showed an association with low vascular endothelial growth factor (VEGF) levels and increased mortality. This current study looks to expand on our prior results and will look at the relationship between tumor necrosis factor alpha (TNFα), C-reactive protein (CRP), VEGF, Homocysteine (Hcy), and CRP to albumin ratio (CAR) in predicting outcomes and severity in spontaneous intracerebral hemorrhage. Methods We conducted a retrospective chart review of patients with spontaneous intracerebral hemorrhage with TNFα, CRP, VEGF, Hcy levels drawn on admission. Albumin and CRP levels on admission were used to calculate CAR. Ninety-nine patients were included in the study. Primary outcomes included death, early neurologic decline (END), and hemorrhage size. Secondary outcomes included late neurologic decline (LND), Glasgow Coma Scale (GCS) on admission, GCS on discharge, ICH score, change in hemorrhage size, need for surgical intervention, and length of ICU stay. Results A total of 99 patients were included in this study, with 42% requiring surgical intervention and an overall mortality of 16%. Basal ganglia hemorrhage was seen in 41% of patients. Hcy and CAR were significantly correlated with ICH size in basal ganglia patients (r-=0.36, p=0.03; r=0.43, p=0.03, respectively). CAR was significantly correlated with ICH score (r=0.33, p=0.007874). Admission VEGF levels less than 45 pg/ml had 8.4-fold increase in mortality (odds ratio [OR] 8.4545, p=0.0488). Patients with TNFα levels greater than 1.40 pg/ml had a 4.1-fold increase in mortality (OR 4.1, p=0.04) Conclusion Our study demonstrated that low levels (<45 pg/ml) of VEGF were associated with an 8.4-fold increase in mortality, supporting the neuroprotective effect of this protein. Elevated Hcy and CAR levels were associated with an increase in hemorrhage size in patients with basal ganglia hemorrhages. TNFα levels greater than 1.40 pg/ml were associated with a 4.1-fold increase in mortality, and this together with CAR being correlated with increased hemorrhage size and ICH score further demonstrate the inflammatory consequences after intracerebral hemorrhage. Future studies directed at lowering CRP, TNFα, and Hcy and/or increasing VEGF in intracerebral hemorrhage patients are needed and may be beneficial.
Copyright © 2021, Bernstein et al.

Entities:  

Keywords:  c-reactive protein; homocysteine; intracerebral hemorrhage; tnf alpha; vegf angiogenesis

Year:  2021        PMID: 33585095      PMCID: PMC7872478          DOI: 10.7759/cureus.12605

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  30 in total

1.  Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury.

Authors:  F C Barone; B Arvin; R F White; A Miller; C L Webb; R N Willette; P G Lysko; G Z Feuerstein
Journal:  Stroke       Date:  1997-06       Impact factor: 7.914

2.  Assessment of relationship between C-reactive protein to albumin ratio and 90-day mortality in patients with acute ischaemic stroke.

Authors:  Mehtap Kocatürk; Özcan Kocatürk
Journal:  Neurol Neurochir Pol       Date:  2019-05-30       Impact factor: 1.621

3.  Serial measurement of vascular endothelial growth factor and transforming growth factor-beta1 in serum of patients with acute ischemic stroke.

Authors:  M Slevin; J Krupinski; A Slowik; P Kumar; A Szczudlik; J Gaffney
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

4.  VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.

Authors:  Z G Zhang; L Zhang; Q Jiang; R Zhang; K Davies; C Powers; N v Bruggen; M Chopp
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

5.  C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score.

Authors:  Mario Di Napoli; Daniel Agustin Godoy; Veronica Campi; Marta del Valle; Gustavo Piñero; Matias Mirofsky; Aurel Popa-Wagner; Luca Masotti; Francesca Papa; Alejandro A Rabinstein
Journal:  Stroke       Date:  2011-04-07       Impact factor: 7.914

6.  C-reactive protein in ischemic stroke: an independent prognostic factor.

Authors:  M Di Napoli; F Papa; V Bocola
Journal:  Stroke       Date:  2001-04       Impact factor: 7.914

7.  High serum levels of growth factors are associated with good outcome in intracerebral hemorrhage.

Authors:  Tomás Sobrino; Susana Arias; Raquel Rodríguez-González; David Brea; Yolanda Silva; Natalia Pérez de la Ossa; Jesús Agulla; Miguel Blanco; José M Pumar; Joaquín Serena; Antoni Dávalos; José Castillo
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-16       Impact factor: 6.200

8.  Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial.

Authors:  Gustavo Saposnik; Joel G Ray; Patrick Sheridan; Matthew McQueen; Eva Lonn
Journal:  Stroke       Date:  2009-02-19       Impact factor: 7.914

9.  Elevated serum IL-11, TNF α, and VEGF expressions contribute to the pathophysiology of hypertensive intracerebral hemorrhage (HICH).

Authors:  Gang Yang; Gao-Feng Shao
Journal:  Neurol Sci       Date:  2016-04-26       Impact factor: 3.307

10.  Impact of Early C-Reactive Protein/Albumin Ratio on Intra-Hospital Mortality Among Patients with Spontaneous Intracerebral Hemorrhage.

Authors:  Michael Bender; Kristin Haferkorn; Michaela Friedrich; Eberhard Uhl; Marco Stein
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.